9/14/2023 0 Comments 10 best stocks to buy nowThat's projected to drop to 20.9% over the next two years, according to analyst estimates, but that could be a conservative outlook given how many opportunities are available to Tandem. Tandem has been an extremely high-growth stock over the past half-decade, with a revenue compound annual growth rate (CAGR) of 52.8% over that time, according to S&P Global Market Intelligence. TNDM estimates there are 9 million people worldwide with type 2 who require intensive insulin therapy, and just 5% use a pump. And none of this takes into account the worldwide opportunity to serve people with type 2 diabetes. is even greater just 12% of people with type 1 diabetes in the countries Tandem serves opt for a pump. However, the opportunity outside the U.S. Of these, only 36% use an insulin pump the rest are on multiple daily insulin (MDI) therapy. But that growth will start here in the U.S., where 1.8 million people suffer from type 1 diabetes. Tandem plans to grow its global installed base of customers from its current level to 1 million people (though it admittedly doesn't provide a timeline). Since 2012, this healthcare stock has grown from negligible revenues to projected sales of at least $850 million in 2022. For the most part, those customers have type 1 diabetes, vary in age, are a mix of men and women, and use continuous glucose monitoring (CGM). Its main product is the t:slim X2 insulin pump, which can hold up to 300 units of insulin but is 38% smaller than some of the competition.Īs of early May, the company boasted more than 350,000 customers worldwide. The main product from Tandem Diabetes Care ( TNDM, $65.67) is pushing the innovation envelope to help its customers cope with their diabetes. Analysts' consensus recommendation: 1.91 (Buy).Analysts' ratings: 5 Strong Buy, 2 Buy, 4 Hold, 0 Sell, 0 Strong Sell.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |